YKL-40, also known as human cartilage glycoprotein-39 (1) , is a member of the 'mammalian chitinase-like proteins'. The gene (CHI3L1) for YKL-40 (2) and its crystallographic structure (3) are known, but the site and mode of binding to cell surface receptors have not yet been described. YKL-40 is a heparin and chitinbinding lectin (4) without chitinase activity (1, 4) . It is produced by macrophages (4, 5) , neutrophils (6) , synovial cells, chondrocytes from arthritic joints (1), differentiating smooth muscle cells, hepatic stellate cells, and cancer cells. The precise biological function of YKL-40 is unknown, but it increases growth rates of fibroblastic cell lines derived from human osteoarthritic synovium, foetal lung and adult skin, and works synergistically with insulin-like growth factor (IGF)-1 in stimulating the growth of fibroblasts (7) . YKL-40 also increases the number of chondrocytes and synovial cells and proteoglycan synthesis (8) . Furthermore, YKL-40 is an adhesion and migration factor for vascular smooth muscle cells (9) and umbilical vein endothelial cells and modulates vascular endothelial cell morphology by promoting the formation of branching tubules. This indicates that YKL-40 may function in angiogenesis. Besides having biological effects, YKL-40 has been shown to be an autoantigen in rheumatoid arthritis.
Elevated serum YKL-40 levels are found in patients with a variety of diseases characterized by inflammation, remodelling of the extracellular matrix, and development of fibrosis, such as rheumatoid arthritis, osteoarthritis, giant cell arteritis, pneumonia, liver fibrosis, and different types of solid tumours (10, 11) . The serum YKL-40 levels vary according to the disease activity of the patients and elevated serum YKL-40 is associated with a poor prognosis.
Systemic sclerosis (SSc) is an autoimmune disease characterized by initial inflammation followed by fibrotic changes in the skin, blood vessels, and several other organs. The pathogenesis of SSc is unclear. However, various growth factors seem to be involved in the fibrotic processes (12) . Elevated serum YKL-40 is found in approximately 30% of patients with SSc and particularly in those with joint involvement (13) . The aim of the present study was to assess whether serum YKL-40 in patients with SSc has clinical and prognostic associations.
Material and methods

Patients
Eighty-eight patients (median age 58 years, range 20-82) who fulfilled the American College of Rheumatology (ACR) preliminary criteria for the classification of SSc were included, and were part of a longitudinally followed population (14) . The patients were selected according to the availability of serum samples collected during the follow-up. The median duration of cutaneous sclerosis was 7.2 years (range 0-39) and the median duration of follow-up after the time of blood sampling was 3.2 years (range 0-17). Skin involvement was diffuse in 26 (30%) patients and limited in 62 (70%). Fifty-five patients were (or had been) treated with penicillamine (300-1200 mg daily, median 750 mg). Skin involvement was classified according to the maximum cutaneous involvement by means of a two-subset model (limited and diffuse involvement; dividing lines: elbows and knees). Demographic data, signs, and symptoms (i.e. gender, age, duration of cutaneous involvement, years of follow-up after blood sampling, digital pitting scars, subcutaneous calcinosis, distal osteolysis, chronic polyarthritis, SSc-related deformities of the finger joints (due to retraction of skin and tendons), and the presence of anti-centromere and anti-Scl70 antibodies, pulmonary fibrosis) were registered at the time of blood sampling: Vital status was obtained from the Danish Central Person Register. Causes of death were based on information obtained from hospital charts, autopsy reports, and death certificates.
Pulmonary imaging and function tests
At inclusion, the patients had pulmonary function tests (PFTs) and routine chest X-ray examinations. The largest of three technically acceptable efforts was used to determine the forced expiratory volume during the first second (FEV1), inspiratory vital capacity (VC), and the ratio of FEV1/VC. The diffusing capacity of CO (DLco) was determined using a single breath helium, CO-dilution technique. The PFT results were transformed to standardized values calculated as percentages of the predicted values with respect to sex, age, and height. Three subsets of patients were delineated: (i) restrictive ventilatory pattern (VC(80% and FEV1/VC >70%), (ii) obstructive ventilatory pattern (FEV1/VCv70%), and (iii) DLco reduced to less than 70% of the expected values. Twenty-seven patients (31%) had radiographically demonstrated pulmonary fibrosis. The ventilatory pattern was restrictive in 17 (19%) patients, obstructive in 11 (13%), and low DLco was found in 39 (44%). In patients with pulmonary fibrosis the median values of VC and DLco were 76% and 56%, respectively, of the expected value.
Serological methods
Serum YKL-40 was determined by an in-house radioimmunoassay (RIA). An age-and sex-matched control population consisting of 70 women and 18 men (median age 58 years, range 21-79) was used to determine the cut-off limit of normal versus elevated serum YKL-40 (i.e. the 95th confidence limit of serum YKL-40 in healthy subjects5275 mg/L).
Statistical analysis
Statistical analyses were performed by means of SPSS for Windows version 10 (SPSS Inc., Chicago, USA) and included the Mann-Whitney rank test, Fisher's exact test, stepwise conditional logistic regression analysis, and survival analyses by means of KaplanMeier plotting, log-rank statistics, and Cox regression analysis. Statistical significance was set at pv0.05.
Results
Serum YKL-40 was higher in the patients (median 161 mg/L, quartiles 112-284 mg/L, 95th percentile 602, pv0.00001) than in the controls (median 104 mg/L, quartiles 89-149 mg/L, 95th percentile 275). Twentyseven per cent had elevated serum YKL-40 (i.e. wthe 95th percentile of the controls). Anticentromere antibodies (ACA) and antitopoisomerase-I antibodies (ATA) were found in 34 and 11 patients, respectively, and did not correlate with serum YKL-40. Table 1 shows serum YKL-40 levels in relation to demographic and clinical features. Serum YKL-40 was significantly elevated in patients with pulmonary fibrosis, obstructive ventilatory pattern, SSc joint deformity, and old age (w60 years). Table 2 shows the demographic and clinical features of the 88 SSc patients stratified according to elevated or normal serum YKL-40. Elevated serum YKL-40 was significantly related to old age, obstructive ventilatory pattern, decreased vital capacity, and diffusing capacity. Elevated serum YKL-40 was not associated with restrictive ventilatory pattern. To evaluate independent contributions to elevated serum YKL-40, a logistic stepwise regression analysis of serum YKL-40 using the factors of Table 2 Immunohistochemical analysis for YKL-40 protein expression in a lung biopsy with inflammation and severe fibrosis from a patient who died of SSc showed YKL-40 expression in macrophages and leucocytes in areas with inflammation (data not shown).
Twenty-two (25%) patients died during follow-up, and 11 of these had elevated serum YKL-40. Nine blood sample than patients with normal serum YKL-40 (p50.004) (Figure 1 ). When controlling for age, reduced vital capacity, and reduced diffusing capacity, patients with increased serum YKL-40 still had the poorest survival, although this was not statistically significant (p50.1).
Discussion
We found elevated serum YKL-40 in 27% of patients with SSc, similar to other reports (13) . SSc patients with various signs of pulmonary involvement had elevated serum YKL-40, and this was associated with features of obstructive lung disease and decreased vital and diffusing pulmonary capacity. The cellular abnormalities in SSc lungs often result in complex alterations of the lung function. Interstitial fibrosis, vascular lesions including fibrous thickening of the intima, media hypertrophy, and perivascular fibrosis may lead to a restrictive lung function pattern and/or impairment of the diffusing capacity. High serum YKL-40 was related to reduced DLco, possibly caused by interstitial and perivascular fibrosis.
Interestingly, the present study shows that SSc patients with elevated serum YKL-40 had shorter survival than patients with normal serum YKL-40 and died more often due to extensive interstitial or vascular fibrosing processes (e.g. pulmonary fibrosis, SSc renal crisis). However, this association is partly explained by age, reduced vital capacity, and reduced diffusing capacity.
Immunohistochemical analysis of a lung biopsy from an SSc patient with lung inflammation and fibrosis showed YKL-40 protein expression in macrophages and neutrophils in areas with inflammation. YKL-40 is a growth factor for fibroblasts (7), but it is not known whether YKL-40 plays a role in the pathogenesis of pulmonary fibrosis in patients with SSc. YKL-40 may actively take part in inflammation and tissue remodelling processes and has a role in pathological conditions leading to organ fibrosis. YKL-40 was one of the most differentially expressed genes in liver tissue with hepatitis C cirrhosis (15) and serum YKL-40 was elevated in most patients with moderate to severe liver fibrosis and cirrhosis, independently of disease aetiology (11) associated with shorter survival of patients with alcoholic liver disease compared to patients with normal serum YKL-40.
The precise role of YKL-40 in the pathogenesis of pulmonary fibrosis in SSc is still unknown and large prospective studies of patients with SSc are needed to determine any prognostic significance of high serum YKL-40.
